We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00386464
Recruitment Status : Completed
First Posted : October 11, 2006
Last Update Posted : November 9, 2007
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:
Johns Hopkins University

Brief Summary:

Non-invasive ventilation or BiPAP®, which is a form of breathing support delivered through a facemask, is a successful treatment for the respiratory complications of amyotrophic lateral sclerosis (ALS). It has been shown to prolong survival, improve quality of life, and improve cognitive function. It is widely used among patients with ALS who have advanced breathing difficulties. It is not known whether there is benefit to using non-invasive ventilation earlier in the disease course.

There is evidence that non-invasive ventilation may slow down the decline in breathing function. If this were true then it would make sense to start non-invasive ventilation use earlier than the current clinically accepted practices.

The purpose of this study is to determine whether using non-invasive ventilation early in the course of disease can slow the decline in breathing function.

Patients remain in the study for 6 months and are asked to make 7 clinic visits during which time they will undergo pulmonary function tests and complete questionnaires.

Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Device: noninvasive positive pressure ventilation Phase 2 Phase 3

Detailed Description:
This is a randomized, crossover trial for patient with ALS and mild respiratory involvement. Patients with forced vital capacity above 60% of the predicted value can join. Patients will be assigned to either start using non-invasive ventilation at night or continue their usual care. After three months, patients will switch over to the other treatment group. For example, a patient who was initially assigned to continue their usual care would begin using non-invasive ventilation after three months.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement
Study Start Date : April 2002
Study Completion Date : September 2007

Primary Outcome Measures :
  1. Decline in forced vital capacity

Secondary Outcome Measures :
  1. quality of life
  2. respiratory quality of life

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Probable or definite ALS by El Escorial criteria
  • age >17 years
  • FVC >60
  • minimal respiratory symptoms (no orthopnea or dyspnea at rest)
  • ability to provide informed consent

Exclusion Criteria:

  • Presence of another neurodegenerative disease
  • arterial CO2 above 45 mmHg
  • O2 below 60 mmHg
  • coexisting chronic lung disease unrelated to ALS
  • presence of an unstable medical condition such as coronary artery disease, liver failure, renal failure or cancer in the 30 days preceding enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00386464

United States, Maryland
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21205
Sponsors and Collaborators
Johns Hopkins University
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Noah Lechtzin, MD Johns Hopkins University
Study Chair: Charles M Wiener, MD Johns Hopkins University

Additional Information:
ClinicalTrials.gov Identifier: NCT00386464     History of Changes
Other Study ID Numbers: HL 67887-03
First Posted: October 11, 2006    Key Record Dates
Last Update Posted: November 9, 2007
Last Verified: April 2007

Keywords provided by Johns Hopkins University:
lou gehrigs disease
motor neuron disease
respiratory muscles

Additional relevant MeSH terms:
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases